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1. Introduction
Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality 
in hospitalized patients and the immunocompromised populations. Candidemia, 
invasive aspergillosis, mucormycosis, cryptococcosis, and Pneumocystis pneumonia 
(PCP) are IFIs associated with the highest incidence and mortality. The broader use 
of more aggressive treatment modalities, such as hematopoietic stem cell transplanta-
tion (HSCT) and solid organ transplantation (SOT), as well as chemotherapy for 
cancer patients and prolonged corticosteroid therapy, has increased the population of 
immunocompromised patients at risk for IFIs. Other groups at risk include individu-
als who have HIV/AIDS in which PCP is an AIDS-defining disease [1]. In this chapter, 
we aim to overview the epidemiology of the leading causes of IFIs in humans.
2. Aspergillosis
The genus Aspergillus contains more than 300 species described and is divided 
into 20 sections [2]. However, only a few are known to cause human disease. Human 
aspergillosis is primarily caused by Aspergillus fumigatus (the most common spe-
cies described in aspergillosis cases), A. flavus, A. niger, A. terreus, and A. nidulans. 
Aspergillus species are ubiquitous, are found in soil and several organic debris, 
and produce conidia that are easily aerosolized. These conidia, when inhaled, can 
colonize the host’s lungs, which can develop various clinical syndromes depending 
on their degree of immunocompetence. Ingestion of spores via the gastrointestinal 
tract or direct inoculation via skin injuries is an uncommon way of inoculation [3–5].
The major risk factors for infection include prolonged neutropenia, HSCT, 
SOT, corticosteroid therapy, chronic granulomatous disease, immunosuppressive 
treatment for malignancies, hematologic malignancy, myelodysplastic syndrome or 
aplastic anemia, advanced stage of human immunodeficiency virus (HIV) infection 
(facilitated by low CD4+ cell counts), previous infections (such as cytomegalovi-
rus infection), and patients with critical illness [4, 6]. The spectrum of disease is 
determined by the host’s immune status and the virulence of Aspergillus species.
In immunocompetent hosts, aspergillosis causes mainly allergic symptoms 
without invasion and destruction of the host’s tissues and chronic pulmonary asper-
gillosis. Allergic bronchopulmonary aspergillosis (ABPA) is a syndrome that arises 
from a hypersensitivity reaction to antigens from Aspergillus and may be developed 
in patients with asthma and cystic fibrosis [7]. In the chronic pulmonary aspergil-
losis, a preexisting pulmonary condition is generally observed. Chronic cavitary 
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pulmonary aspergillosis (aspergilloma or fungus ball) is the best-recognized form 
of pulmonary involvement due to Aspergillus, usually occurring in a preformed 
cavity in the lung (due to tuberculosis, sarcoidosis, or other necrotizing pulmonary 
processes) or in the paranasal sinuses [8, 9]. Subacute invasive aspergillosis (also 
called chronic necrotizing pulmonary aspergillosis) is a locally destructive invasion 
of lung parenchyma without invasion or dissemination to other organs [9, 10].
In immunocompromised patients, invasive aspergillosis (IA) can be a rapidly, 
progressive and frequently fatal disease. Invasive pulmonary aspergillosis (IPA) 
and rhinocerebral aspergillosis are the most common clinical forms of IA. Other 
clinical conditions included tracheobronchitis, invasive Aspergillus infection of 
the eye or heart, gastrointestinal invasive aspergillosis, cutaneous aspergillosis, 
and disseminated invasive aspergillosis [5]. Data from the Transplant-Associated 
Infection Surveillance Network (TRANSNET) [11] described that in HSCT 
recipients, invasive aspergillosis was the most common IFI (425 cases, 43%), 
followed by invasive candidiasis (276 cases, 28%) and zygomycosis (77 cases; 8%). 
One-year overall mortality rate reaches 75% [11]. In the Prospective Antifungal 
Therapy Alliance (PATH Alliance®) registry, from a cohort study of 960 cases 
of proven/probable IA, 48.3% of patients had hematologic malignancy, 29.2% 
received SOT, 27.9% were HSCT recipients, and 33.8% were neutropenic. The lung 
was the organ most frequently affected (76% of cases). The tracheobronchial tree, 
sinuses, skin, soft tissues, and the central nervous system were the most common 
extrapulmonary sites of infections. The most predominant species was A. fumiga-
tus (72.6%), followed by A. flavus (9.9%), A. niger (8.7%), and A. terreus (4.3%). 
Overall Kaplan-Meier survival (12-week post-diagnosis) among all patients with 
IA was 64.4%.
3. Candidiasis
Candida species are ubiquitous yeasts, being frequent colonizers of the skin and 
normal flora of mucocutaneous membranes of humans. Also, it was also recovered 
from soil, hospital environment, food, inanimate objects, and nonanimal environ-
ments [12]. Candida albicans, Candida dubliniensis, Candida glabrata, Candida guil-
liermondii, Candida intermedia, Candida kefyr, Candida krusei, Candida lusitaniae, 
Candida parapsilosis, Candida pseudotropicalis, Candida stellatoidea, and Candida 
tropicalis are the main species associated with candidiasis, although more than 200 
species of Candida have been identified.
Candida albicans remains the predominant species in most studies [13]. 
However, a shift in the etiology can be observed in different regions of the world 
[14]. For example, in northwestern Europe and the United States, Candida glabrata 
is generally recovered as the most common species, whereas in Southern Europe, 
some Asian countries and Latin America, Candida parapsilosis and Candida tropi-
calis are more frequently recovered than Candida glabrata. Of notable concern is 
the emergence of Candida auris, a multiresistant species associated with outbreaks 
of candidemia in many countries that presents a serious global health threat [12, 
14–16].
As opportunistic pathogens, Candida infections can occur due to factors related 
to the host, the microorganism, or both. The three major conditions that predispose 
the human infection are: (i) the use of broad-spectrum antibiotics (long-term 
and/or repeated use), (ii) mucosal barrier breakdown, such as those induced by 
cytotoxic chemotherapy and medical interventions, and (iii) iatrogenic immuno-
suppression, such as corticosteroid therapy or chemotherapy-induced neutropenia 
[15]. Long hospital or intensive care unit (ICU) stay is the most common health 
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care-associated risk [17]. Among the several virulence factors described for 
Candida, (i) the ability of most species to switch between yeast, pseudohypha, 
and hyphae morphotypes; (ii) the secretion of a variety of factors, such as secreted 
aspartyl proteases, phospholipases and candidalysin toxin; and (iii) the effective 
capacity of adherence (mediated by proteins such as agglutinin-like protein 3) and 
biofilm formation are the main microorganism-related factors that contribute to 
candidiasis [15].
The incidence of Candida infections varies according to several epidemiologi-
cal and geographic characteristics. Candida species are among the top four main 
pathogens causing health care-associated bloodstream infections, particularly in 
ICU, affecting 250,000 people and causing more than 50,000 deaths worldwide 
every year, based on conservative estimates [18–20]. In an international study of 
prevalence and outcomes of infection in ICU, Candida was the third most common 
cause of infection (17%), after Staphylococcus aureus (20.5%) and Pseudomonas 
species (19.9%) [21].
Candida was the most common fungal pathogen that causes invasive infection 
in SOT population [22]. In bone marrow transplantation (BMT) under flucon-
azole prophylaxis, Aspergillus species replaced Candida as main cause of IFI [11]. 
Newborn infants [23], HIV-infected patient (without the use of antiretroviral 
therapy) [24], and patients who underwent abdominal surgery [25] are other 
populations at increased risk for Candida infections. Unadjusted mortality rates 
vary widely (from 29 to 76%) for candidemia. In the United States, the attributed 
mortality rate ranges from >30 to 40% and the median cost for inpatient care was 
$46,684 [15, 19, 26, 27].
4. Cryptococcosis
Cryptococcus neoformans and Cryptococcus gattii are the two species that com-
monly cause cryptococcosis in humans. Historically, these species were classified 
into three varieties, five serotypes, and eight molecular subtypes. However, based 
on phylogenetic and genotyping studies, it was proposed to split Cryptococcus neo-
formans into two species (Cryptococcus deneoformans and Cryptococcus neoformans) 
and Cryptococcus gattii into five species (Cryptococcus bacillisporus, Cryptococcus 
decagatti, Cryptococcus deuterogattii, Cryptococcus gattii, and Cryptococcus tetragattii)  
[28]. Nonetheless, considering that more data about the genetic diversity of 
Cryptococcus were recently described and the absence of defined biological and 
clinical differences between the seven new species, some authors recommend the 
use of “Cryptococcus neoformans species complex” and “Cryptococcus gattii species 
complex” as a practical intermediate step until this species differentiation is clini-
cally relevant [29].
Cryptococcus neoformans has been isolated in decaying material within hollows of 
several tree species, fruit, and soil enriched by avian excreta (such as feral pigeons) 
and is globally distributed. Cryptococcus gattii is classically associated with eucalyp-
tus tree and limited to tropical and subtropical regions. However, recent outbreaks 
in Canada, Northern Europe, and Northern USA suggest that the ecological range 
of this species may not be fully recognized. Both species can survive and replicate in 
environmental scavengers such as free-living amoebae and nematodes [30, 31]. The 
respiratory tract is the main portal of entry for the aerosolized infectious particles 
from the disrupted and contaminated environment (soil, tree, or bird droppings-
enriched areas). Lung and the central nervous system (CNS) are the primary sites 
of infection, but eyes, prostate, and skin can be frequently involved. Traumatic 
inoculation may occur but is infrequent [31–33].
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HIV infection, idiopathic CD4+ lymphopenia, corticosteroid treatment, SOT, 
malignant and lymphoproliferative disorders, sarcoidosis, treatment with some 
monoclonal antibodies (such as alemtuzumab, infliximab, etanercept, adalimumab, 
or anti-GM CSF), rheumatologic diseases (such as systemic lupus erythematosus 
and rheumatoid arthritis), chronic liver disease, renal failure and/or peritoneal 
dialysis, hyper-IgM syndrome or hyper-IgE syndrome are the main risk factors for 
cryptococcosis [31, 33, 34].
Cryptococcus infections in humans were considered uncommon before the 
1970s. Cryptococcosis incidence increased significantly in the HIV epidemics in 
the 1980s. The overall incidence of 0.8 cases per million persons per year in the 
pre-AIDS era reached almost five cases per 100,000 persons per year in the peak of 
the AIDS epidemic. The incidence of cryptococcosis declined and stabilized from 
the mid-1990s with the use of fluconazole for the treatment of oral candidiasis and 
with the widespread use of active antiretroviral therapy (ART) [34–36]. However, 
HIV-associated cryptococcosis mortality remains unacceptably high, and globally, 
cryptococcal meningitis accounts for 15% of AIDS-related deaths. Cryptococcal 
infection-related deaths were estimated at 181,100 globally, with 75% (135,900) 
occurring in sub-Saharan Africa [37–39].
In HIV-negative individuals, cryptococcosis occurs in transplant recipients and other 
patients with primary or acquired defects in cell-mediated immunity [32]. In a recently 
multicenter, longitudinal cohort study in the United States [40], the demographics 
of 145 HIV-negative patients with cryptococcosis demonstrated that SOT (49 cases, 
33.8%) was the main underlying disease, followed by autoimmune syndromes (15.9%), 
hematologic malignancy (11.7%), decompensated liver disease (9.7%), solid tumor 
(5.6%), primary immunodeficiency (2.1%), and HSCT (2.8%). Glucocorticoid therapy 
and cytotoxic chemotherapy were the immunosuppressive medications described for 
more than 40% of patients. CNS involvement was observed in 71 patients (49%).
5. Mucormycosis
Rhizopus is the most common genera causative of human disease, followed 
by Mucor, Lichtheimia, Apophysomyces, Rhizomucor, and Cunninghamella spe-
cies. Less frequently, members include Actinomucor, Cokeromyces, Saksenaea, and 
Syncephalastrum [41–43]. These members from Mucorales family are ubiquitous 
in the environment, are taken by the host via inhalation of spores or ingestion of 
contaminated food, but rarely cause infection without obvious predisposing host 
factors [44].
Uncontrolled diabetes, hematological malignancy, malnutrition, solid organ 
transplantation, hematopoietic stem cell transplant, and liver disease are the primary 
underlying conditions associated with mucormycosis. Predisposing factors include 
corticosteroid use, neutropenia, trauma, anticancer therapy, use of calcineurin 
inhibitors, biological and renal replacement therapies, prior antifungal prophylaxis 
(e.g., voriconazole), iron overload and deferoxamine therapy [41, 42, 44].
Rhinocerebral, pulmonary, cutaneous, gastrointestinal, and disseminated 
mucormycosis are the common types of disease described. The mortality and mor-
bidity rates are dependent on affected organ, Mucorales species, and medical status 
of the patient. Mucormycosis can be an extremely aggressive disease, and mortality 
rates can reach 46% in sinus infection, 73% in mucormycosis after exposure to vori-
conazole, 76% in pulmonary disease, and 96% in disseminated infections [42, 45].
Based on autopsy reports [46], mucormycosis is the third most common cause 
of invasive fungal infection, after candidiasis and aspergillosis. In developed 
countries, hematologic malignancies and hematopoietic stem cell transplantation 
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are the leading underlying conditions in mucormycosis cases while in develop-
ing countries, particularly in India, the major causes of the disease are associated 
with uncontrolled diabetes or trauma [43, 47]. Data from Transplant-Associated 
Infection Surveillance Network show that mucormycosis (formerly zygomycosis) 
was the third most common IFI (8%) in HSCT [11] and sixth most common IFI 
(2%) among organ transplant recipients [22].
6. Pneumocystis
Pneumocystis jirovecii (previously Pneumocystis carinii f. sp. hominis) is an oppor-
tunistic pathogen causing pneumonia in patients with immunodeficiencies and can 
colonize the lung of healthy individuals. Initially classified as a protozoan species, it 
is now recognized as a fungus based on phylogenetic data and the genus comprising 
a group of highly diversified species with a high degree of hosts-species specificity 
[48]. The environmental reservoir was not identified so that the mammalian hosts 
can be considered as reservoirs. Indeed, it was demonstrated that close person-to-
person contact could facilitate the transmission, and nosocomial transmission has 
been reported [48, 49].
Despite the genus Pneumocystis being known for years, its life cycle remains poorly 
understood, principally by the lack of a reliable continuous culture system. The 
hypothesized life cycle comprises different morphologic forms: trophozoites, cysts, 
and intracystic bodies (sporozoites) and all these forms reside in the alveoli of the 
lung with the cyst being considered the infectant and transmissible form [48, 50]. 
Evidence suggests that the gateway to infection is through inhalation since controlled 
studies in different animal models have demonstrated airborne transmission [48, 51]. 
As the organism is host specific, transmission from animals to humans is unlikely [51].
The occurrence of Pneumocystis pneumonia (PCP) is related to severely immuno-
compromised people, principally in HIV/AIDS patients, and with other immunosup-
pressed conditions, that is, cancers, autoimmune disorders, transplantation, chronic 
lung disease, especially obstructive pulmonary disease (COPD) [48]. Colonization 
rates have been reported on the order of 20–69% for HIV patients, from 0 to 20% for 
healthy adults, and in 6% of organ transplant recipients if no prophylaxis is given 
[51]. Primary exposure appears to occur at early childhood as demonstrated by the 
seroconversion seen in 85% of children up to 20 months of age [52]. Colonization of 
both children and adults may be a source of transmission of Pneumocystis jirovecii, 
serving as potential reservoirs. Guidelines for prevention and treatment of oppor-
tunistic infections in HIV-infected adults and adolescents include: treating patients 
with PCP together with prophylaxis of susceptible individuals (HIV patients with 
CD4 counts of <200 cells/μl or CD4 percentages of <14%); it is also recommended 
that a patient with PCP should not be placed in the same room with an immunodefi-
cient patient. The prophylaxis among transplant recipients has been proved to be the 
most effective approach for ending outbreaks of PCP [48, 53].
7. Conclusions
The changes in the spectrum of the fungal infections associated with new risk 
factors and the emergence of resistant fungi highlight the necessity of a continuous 
update on knowledge of the epidemiology of fungal infections. Besides, the reduc-
tion of mortality among patients with IFIs must be accompanied by research that 
allows the development of new antifungal treatment strategies and earlier diagnosis 
by traditional and non-culture-based molecular tests.
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